Detoxification and counseling-only aftercare have been treatment mainstays for patients with opioid use disorder. Since long-term abstinence is rarely achieved, additional treatment with medication has been increasing. In the USA, buprenorphine-naloxone (BUP-NX) is the most commonly prescribed agent for medication-assisted opioid treatment. Naltrexone is similarly employed in patients diagnosed with an opioid use disorder. It is available in a long-acting, injectable form (XR-NTX); however, concerns surrounding induction limit its use to well selected individuals. A concurrent Norwegian study concluded that XR-NTX is noninferior to BUP-NX for preventing short-term relapse to opioid use.
Background
Detoxification and counseling-only aftercare have been treatment mainstays for patients with opioid use disorder. Since long-term abstinence is rarely achieved, additional treatment with medication has been increasing. In the USA, buprenorphine-naloxone (BUP-NX) is the most commonly prescribed agent for medication-assisted opioid treatment. Naltrexone is similarly employed in patients diagnosed with an opioid use disorder. It is available in a long-acting, injectable form (XR-NTX); however, concerns surrounding induction limit its use to well selected individuals. A concurrent Norwegian study concluded that XR-NTX is noninferior to BUP-NX for preventing short-term relapse to opioid use.
Research Questions
Is there a difference in relapse rate between patients receiving XR-NTX and those receiving BUP-NX? Are there differences in induction success, safety, and frequency of non-study opioid use?
Methods
This was a 24-week, multicenter, open-label, and randomized trial including subjects who had been admitted to inpatient detoxification centers. Subjects were randomized to receive~380 mg of XR-NTX every 28 days or daily doses of 8-24 mg BUP-NX, supplied weekly. Those randomized to the XR-NTX group were required to have an opioid-negative urine screen and negative naloxone challenge before initiating treatment. Withdrawal symptoms were managed according to usual care at each study site. After discharge from the inpatient center, subjects had weekly office visits out to 24 weeks, then again at 28 and 36 weeks. Psychosocial counseling was available to all subjects.
Results
Five hundred seventy subjects were randomized, 283 to the XR-NTX group and 287 to the BUP-NX group. Two hundred four (72%) subjects in the XR-NTX and 270 (94%) in the BUP-NX group successfully initiated treatment (p < 0.0001). In an intention-to-treat analysis, 185 (65%) subjects in the XR-NTX group and 163 (57%) in the BUP-NX group had relapsed to non-study opioid use by 24 weeks post-randomization (HR 1.36, 95% CI 1.10-1.68). In a per-protocol analysis, there was no significant difference in relapse rate between the two groups. Secondary analysis found similar results with respect to opioidnegative urine samples and self-reported opioid-free days. Cravings were initially better controlled in the XR-NTX group; however, there was no significant difference at week 24. Finally, the frequencies of adverse drug effects, overdose, and overdose deaths did not differ between groups.
Conclusion
Initiation of therapy is more difficult with XR-NTX than BUP-NX. Once subjects were started on therapy, both medications had similar relapse rates and side effect profiles.
Critique
The study recruited subjects who were already admitted to intensive inpatient treatment centers, and these centers used different detoxification protocols. Successful initiation of XR-NTX will likely be even more difficult in the outpatient and emergency department settings. Furthermore, the authors' focus on the intention-to-treat analysis may bias readers' conclusions.
Implication for Toxicologists
XR-NTX and BUP-NX are similarly safe and effective agents used for medication-assisted treatment for opioid use disorder. Toxicologists providing addiction medicine consultations should consider individual patient and institutional factors before selecting a therapeutic agent. 
Article Title

Background
In March 2011, the Fukushima Daiichi Nuclear Power Plant (FDNPP) released several radionuclides after the Great East Japan Earthquake and Tsunami including 131 I, 134 Cs, and 137 Cs. Based on the World Health Organization (WHO) initial health risk assessment, there was a concern for an increased incidence of thyroid cancer cases in radiation-exposed children.
Research Question
Was there an increase in the incidence of thyroid cancer among residents ≤ 18 years exposed to radioactive iodine released from the FDNPP?
Methods
This was a prospective cohort study of all residents in the Fukushima district ≤ 18 years of age in March of 2011. Subjects were screened twice, using thyroid ultrasound (US); first, between 2011 and 2013, and second, between April 2014 and March 2016. Subjects were divided into nine groups based on their home's distance from the FDNPP: nearest (n = 1), middle (n = 4), and least contaminated areas (n = 4). Subjects in the nearest area were screened first over a period of about 1 year. Thyroid cancer was defined as the results of fine needle biopsy, which was performed after two (screening and confirmatory) suggestive US results. Two comparisons of each group's rate of thyroid cancer were made; internal (using the least exposed district, with the lowest prevalence of cancer at 332 per million, as a reference) and external (estimated mean annual incidence rate of pediatric thyroid cancer in Japan; three cases per million).
Results
A total of 298,577 (81%) of the eligible subjects had first round screening by the end of December 2014. There were 2251 US screen-positive cases and 2067 (91%) had secondary examinations, which detected 110 thyroid cancer cases via cytology. Of the 87 cases that underwent surgery, 86 were histologically confirmed carcinomas (83 papillary type; 3 non-differentiated) with one benign tumor. In the second round of screening which included 106,068 (49%) of the eligible candidates, 22 (8%) went on to be examined by fine needle aspiration and eight new thyroid cancer cases was detected by cytology.
Conclusion
There was an increased detection of pediatric thyroid cancer cases following the FDNPP release of radioiodine. Increased incidents of thyroid cancer were noted at both the first and second screenings. Even though precise measurements of radiation exposure in Fukushima were not obtained, among children and adolescents in the Fukushima district, there was approximately a 30-fold increase in thyroid cancer detection within 4 years of the power plant accident.
Critique
This article contained a number of limitations. Including the screening effect, the latency period for developing thyroid cancer following the radiation exposure was shorter (less than 4 years) than what was previously accepted in the literature. The most commonly cited reference is the Chernobyl accident in 1986. In that study, the vast majority of new thyroid cases were diagnosed 4-10 years from the date of the release. Another dissimilarity between the results of this study and the Chernobyl accident is the age groups affected; the Chernobyl accident involved children between 0 and 5 years, while this study involved primarily older (6-17 years) children. Consequently, because of these two differences, previous criticisms have attributed the results in this study to the screening effect. This implies that the increase incidence of thyroid cancer was likely caused by increased screening and unrelated to the radiation exposure. The authors mention this in their discussion but conclude that the screening effect was too large to sufficiently account for the 30-fold increase in the incidence of thyroid cancer compared to the adopted baseline. Another limitation involved no Bdosimetry (exposure assessment)^discussed in the study design. Although radiation-induced cancer is a stochastic effect, we expect that people who have received a higher radiation dose to have a greater risk of developing the cancer. Relying on home addresses is not an adequate surrogate for dose assessment. There are many variables that affect the dose of radiation received by individual subjects, including intake of contaminated food, water, or milk; whether they sheltered in place or were exposed to the plume of radioactive material; and their whereabouts during and after the release of the radioactive material.
Implication for Toxicologists
As the field of radiation epidemiology continues to expand, it is important for medical toxicologists to interpret and understand radiological study design. This will assist them in assessing risk of acute and long-term clinical and public health consequences of radiation emergencies. 
Article Title
Background
The Islamic Republic of Iran shares a border with Afghanistan, the primary worldwide producer of illicit opium. A 2011 national household survey regarding illicit drug use resulted in an estimated 12-month prevalence of 2.23% opium use disorder in Iran. Opiates are currently among the main causes of poisoning in Iran and lead contamination of opium supplies is a known public health issue, particularly for those using opium orally. In February 2016, the authors noticed an increase in opium users presenting to their academic hospital and poison center with severe abdominal pain, anemia, and constipation.
Research Question
What were the characteristic features of a lead poisoning outbreak (and the associated public health response) among opium users in the Islamic Republic of Iran?
Methods
This was a descriptive, observational-type epidemiologic study between February, 2016 and August, 2017 . BSuspected cases^of lead toxicity were defined as having a history of lead exposure (occupational or oral opium use) in combination with either lead-associated health effects (e.g., abdominal colic, pallor, or lead lines), or two pre-determined (less specific) clinical manifestations (e.g., prolonged constipation, weakness, headache, impatience, drowsiness, agitation, or irritability); a third definition included no history of lead exposure but three pre-specified, clinical manifestations of lead toxicity. BProbable cases^were defined as a possible history of lead exposure but without definitive diagnosis. A Bconfirmed case^was any probable case with a measured blood lead level (BLL) ≥ 10 μg/dL. Recorded outcome variables included estimated prevalence of at-risk population, BLLs (among a subset of patients), primary public health response treatments and therapies (including chelation with dimercaprol, dimercaptosuccinic acid (succimer), sodium calcium edetate, or D-penicillamine for symptomatic patients with BLL ≥ 40 μg/dL), number of individuals treated and deaths. Information concerning use of opioid substitution medications and lead chelation agents was obtained from the Iranian Food and Drug Administration. The cause and location of the lead adulteration was also analyzed.
Results
The authors report that the first cases were observed through routine care of opium users with abdominal pain who did not respond to opioid replacement therapy and ultimately found to have elevated BLL. Random blood testing in the opium using population demonstrated further cases of elevated BLL. These findings prompted a response from the Health Ministry with concerted efforts to identify and treat more patients and prevent further exposures. The authors estimated that 42,940 cases of lead toxicity from oral opium abuse were possibly treated nationwide during the 19-month study period; of these, there were 15 deaths attributed to this outbreak. A further 260,000 opium users were estimated to be at (continued) risk of lead poisoning. Due to resource constraints, not all patients had BLLs drawn, but a subset of 80 hospitalized subjects was found to have a mean presenting BLL of 140.3 μg/dL (SD 122.6; range 47.3-1124 μg/dL). Analysis of opium samples obtained from one case patient showed 3.55 mg of lead per 1 g of opium.
The initial public health response focused on exposure reduction and involved a national media campaign focused on encouraging opium users to seek treatment in substance abuse clinics. These opioid treatment clinics utilize opioid substitution with either methadone, buprenorphine, or tincture of opium. Other symptomatic treatments included laxatives, n-acetylcysteine, vitamins C and E, calcium, and iron supplements for constipation, malnutrition, and anemia.
Patients, for whom symptoms did not resolve after exposure removal, were referred for chelation if their blood lead levels are ≥ 40 μg/dL. A total of 19,960 patients were treated with chelation therapy. Based on availability, the most commonly used chelator was D-penicillamine (n = 16,666 patients; 83.4%).
Based on border seizures of opium, it was determined that the lead adulteration most likely occurred within Iran, potentially for the purpose of increasing product weight and financial yield.
Conclusion
An outbreak of lead poisoning in the Islamic Republic of Iran was the result of adulterated oral opium supplies. A small sample of patients had a mean blood lead level of 140 μg/ dL. Estimated outcomes included > 300,000 human exposures, almost 43,000 treated patients (19,960 being chelated) and 15 deaths.
Critique
This was a comprehensive review of an ongoing toxicological outbreak and the commensurate public health response. The used case definitions included subjective variable and allowed for ineffective identification of cases. Only a very small sample (n = 80; 0.19%) of identified patients had BLLs quantified.
Implication for Toxicologists
Although the risk for an outbreak of lead-contaminated opium is not currently an overt and direct risk in the USA, it does highlight (and remind) the need for poison centers, healthcare providers, and government officials to be aware of the potential risk of illicit drug contaminants. While opium is not commonly utilized as an illicit drug in the USA, its use may increase as access to prescription opioids is reduced. Additionally, tainted stock may be utilized to synthesize illicit drugs that are imported to the USA. Poison control centers and medical toxicologists are at the front line in the opioid epidemic, and vigilance for lead toxicity in opioid abusers is warranted.
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